FibroGen (NASDAQ:FGEN) shares traded higher in the pre-market Friday after the renal drugmaker elevated its interim Chief Executive Officer Thane Wettig to the position of permanent CEO and as a board member.
The board of directors made the appointment at a meeting on October 2, the San Francisco, California-based biotech said in a regulatory filing late Thursday.
Mr. Wettig, who served as FGEN’s Chief Commercial Officer since June 2020, was named the company’s interim CEO in July following the departure of Enrique Conterno, who resigned from the CEO position due to personal reasons.
He has over 30 years of global biopharma leadership and commercial experience, FibroGen (FGEN) said at the time.
Mr. Wettig started his career at Eli Lilly (LLY) in 1990 and had previously served as Chief Marketing Officer of the pharma giant’s diabetes segment.